

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.



JD MPH

Silver State Scripts Board Meeting Minutes

Date of Meeting:	Thursday, June 22, 2023, at 1:00 PM
Name of Organization:	The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Scripts Board.

Ag	enda Item	Record	Record							
1.	1. Closed Executive Session									
	a. Call to Order and Roll Call	Chair Mark Decerbo called the meeting to 2023.	 DHCFP Staff Present were as follows: Lither, Gabriel, Senior 							
		Chair Decerbo took the roll.	Present	Absent	 Deputy Attorney General (SDAG) Clemons, Roshanda, MD, 					
		Mark Decerbo, Pharm.D., Chair	\boxtimes		Medicaid Medical Director					
		• Kate Ward, Pharm.D., Vice Chair	\boxtimes		Olsen, David, Social					
		Joseph Adashek, MD	\boxtimes		Services Chief III					
		Mark Crumby, Pharm. D.		\boxtimes	Gudino, Antonio, Social					
		• Elizabeth Gonzalez, Pharm.D.	\boxtimes		Services Program					
		Sapandeep Khurana, MD	\boxtimes		Specialist III (SSPS)					
		• Isabella Niezborala, Pharm.D.	\boxtimes		• Flowers, Ellen, Program					
		• Leana Ramirez, Pharm.D.	\boxtimes		Officer I (PO)					
		Aditi Singh, MD		\boxtimes						

		 Nevada Medication Assistance Program (NMAP) Staff Present were as follows: Johnson, Tory, Health Program Manager II Cowan, Sarah, Health Program Specialist I Magellan Rx Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services Soto, Claudia, Sr. Dir. Account Management Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst
b. Financial Review of Drug Classes with Proposed Changes	 Chair Decerbo directed Dr. Raj Mishra to proceed with the Financial Review of Drug classes with proposed changes up for review. Dr. Mishra reminded the board members that the financial material presented is confidential and should not be discussed or disclosed outside this closed session of the Silver States Scripts Board meeting. 	
	 Dr. Mishra presented the Financial Review of the News Drugs, noting the products with proposed changes in PDL status. INJECTABLE MULTIPLE SCLEROSIS 	
]	Dr. Mishra presented the Financial Review of the Established Drug	

	Classes with Proposed Changes, noting th changes in PDL status. MOVEMENT DISORDERS HEPATITIS C COURSES EPINEPHRINE, SELF-INJECTED ANDROGENIC AGENTS ANTIMIGRAINE AGENTS, OTHER	e products with proposed	
2. Open Public Meeting a. Call to Order and Roll Call	 Chair Decerbo called the meeting to order A quorum was present. Chair Decerbo took the roll. Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	r at 1:48 p.m. on June 22, 2023. Present Absent Image: I	 DHCFP Staff Present were as follows: Lither, Gabriel, SDAG Clemons, Roshanda, MD, Medicaid Medical Director Olsen, David, Social Services Chief III Gudino, Antonio, SSPS III Flowers, Ellen, PO I NMAP Staff Present were as follows: Johnson, Tory, Health Program Manager II Cowan, Sarah, Health Program Specialist I Magellan Rx Staff Present were as follows: Mishra, Raj, Pharm.D., Clinical Account Manager Kim, James, Pharm.D., Dir. Clinical Account Services

			 Soto, Claudia, Sr. Dir. Account Management Martinez, Chris, Sr. Business Analyst Perez, Melissa, Sr. Business Analyst
			The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured
b.	Approval for previous Meeting Minutes from March 23,2023 and April 20, 2023.	By unanimous consent, the minutes were approved.	
c.	Public Comments	Telephonic and web comment was called for, and the phone lines were opened. No public comments were provided.	
d.	NMAP Program: Silver State Scripts Board to serve as the official advisory board	By unanimous consent, Silver State Scripts Board will now serve as the official advisory board for the NMAP Program.	
e.	Status Update by DHCFP	 Chief of Pharmacy Services, David Olsen, provided several announcements. As a result of the 82nd legislative session closing of the state, Medicaid approved budget does include the position of a Medicaid Pharmacy Director. If interested, please feel welcome to send CV's or resumes to our <u>RXinfo@dhcfp.nv.gov</u> email address. I would also like to provide two project updates. Regarding the first project is concerning physician administered drugs. We were 	

 establishing a new prior authorization program, which we announced at the previous meeting is for in-scope drugs for Fee-for-Service recipients with dates of service on or after July 1st of 2023, providers will be able to complete the prior authorization process through the web portal for these drugs and in addition to the prior authorization program for the first time, there will be a fee schedule for physician administered drugs. Please check the rates page on the DHCFP website to see that schedule that goes into effect on July 1st as well. Also, on June 13th the DHCFP held the public workshop to discuss physician administered drugs, also including the Medicare or ESP average sales price based fee schedule and that could be an additional step that the state might take later this year.
 In the last meeting, I did mention that we have an additional member joining our board and this is her first meeting. So, I just wanted to welcome Doctor Leana Ramirez.
f. Status Update by NMAP Health Program Specialist, Sarah Cowan, provided an announcement. • NMAP is adding Sunlenca to the formulary. Sunlenca was approved December 2022 by the US FDA and has been classified as an HIV capsid inhibitor. The recently updated guidelines for the use of antiretroviral agents in adults and adolescents with HIV constitutes a burst in class antiretroviral drug products that must be covered by ADAPs. ADAPs are required by Ryan White HIV/AIDS Program statue to include at least one drug for each class of antiretroviral medications as perception 2616 C, one of the public Health Service Act. Also to be noted that this addition is considered a requirement and no voting is required by the board.
Clinical Presentations

anc Inje	Possible Action: Discussion possible adoption of ectable Multiple Sclerosis ents.					
i.	<u>Public comment</u>	Telephonic and web comment was called opened. Public comment was provided by Melissa Medical Affairs.				
ii.	Drug class review presentation by MagellanRx	Dr. Mishra discussed Briumvi, the new pr presented the availability within the drug mechanism of action, and efficacy studies Dr. Mishra recommended the Board cons therapeutically equivalent.				
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Joseph Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan, and Chair Decerbo seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. 	Yes ⊠ ⊠ □ ∞ ∞	No	Abst.	

	• Leana Ramirez, Pharm.D.	\boxtimes			
	Aditi Singh, MD			\boxtimes	
				—	
iv. Presentation of	Dr. Mishra recommended adding Brium	vi on the PDI	L as no	n-preferred.	
recommendations for PDL					
inclusion by MagellanRx					
v. Discussion by Board and action by Board for	Board Member Adashek moved to appro			-	
approval of drugs for	presented by Magellan and Board Mem the motion.	per Elizabeli	GONZ	alez seconded	
inclusion on the PDL.					
	A vote was taken, and the results were a	as follows fro	m mer	nbers in	
	attendance (in favor, against, and abste	ntions where	e appli	cable):	
		Yes	No	Abst.	
	Mark Decerbo, Pharm.D., Chair	\boxtimes			
	• Kate Ward, Pharm.D., Vice Chair	\boxtimes			
	Joseph Adashek, MD	\boxtimes			
	Mark Crumby, Pharm.D.			\boxtimes	
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes			
	 Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. 	\boxtimes			
	 Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. 	\boxtimes			
	 Aditi Singh, MD 			\square	
B. For Possible Action: Discussion					
and possible adoption of					
Movement Disorders.					
i. <u>Public comment</u>	Telephonic and web comment was calle	ed for, and th	e phor	ne lines were	
	opened.				
	Bublic comment was provided by Mand	oon Silval Dk	Jarmar	sist with Toyo	
	Public comment was provided by Mand	eep silval, Pr	aiiid	JSC WILLI IEVd	

		Medical Affairs.		
ii.	Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board cons therapeutically equivalent.	ider the class clinically and	
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Vice-Chair Kate Ward moved to accept to therapeutically equivalent presented by Adashek seconded the motion. A vote was taken, and the results were a attendance (in favor, against, and abster	Magellan and Board Member s follows from members in	
		 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes No Abst. Image:	
iv	 Presentation of recommendations for PDL inclusion by MagellanRx 	Dr. Mishra recommended adding Austec preferred.	do XR on the PDL as non-	
v.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to appropriate presented by Magellan and Board Member Motion.	ber Gonzalez seconded the	

	attendance (in favor, against, and abstentions where applica	ble):
	YesNoMark Decerbo, Pharm.D., ChairIKate Ward, Pharm.D., Vice ChairIJoseph Adashek, MDIMark Crumby, Pharm.D.IElizabeth Gonzalez, Pharm.D.ISapandeep Khurana, MDIIsabella Niezborala, Pharm.D.ILeana Ramirez, Pharm.D.IAditi Singh, MDI	Abst.
C. For Possible Action: Discussion and possible adoption of Anti- hepatitis Agents – Polymerase Inhibitors/Combination Products		
i. <u>Public Comment</u>	Telephonic and web comment was called for, and the phone opened. Public comment was provided by John Phoenix, Nurse Pract the Huntridge Family Clinic in Las Vegas.	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinica therapeutically equivalent.	ally and
iii. Discussion by Board and action by Board to approve clinical/therapeutic	Board Member Gonzalez moved to accept the class as clinica therapeutically equivalent presented by Magellan and Board Adashek seconded the motion.	

equiva	alency of agents in	A vote was taken, and the results were as follows from members in					
class.		attendance (in favor, against, and abstentions where applicable):					
					Yes	No	Abst.
		•	Mark Decerbo, Pharm.D., Chair		\boxtimes		
		•	Kate Ward, Pharm.D., Vice Chair		\boxtimes		
		٠	Joseph Adashek, MD		\boxtimes		
		٠	Mark Crumby, Pharm.D.				\boxtimes
		٠	Elizabeth Gonzalez, Pharm.D.		\boxtimes		
		٠	Sapandeep Khurana, MD		\boxtimes		
		٠	Isabella Niezborala, Pharm.D.		\boxtimes		
		٠	Leana Ramirez, Pharm.D.		\boxtimes		
		٠	Aditi Singh, MD				\boxtimes
						<u>,</u>	
iv. Presei		D	r. Mishra recommended moving E	pclusa as n	ion-pr	eferrec	1.
	nmendations for		loving Homeni to non proferred				
	nclusion by llanRx	IV	loving Harvoni to non-preferred.				
Iviage	IIdIIIX	M	loving ledipasvir/sofosbuvir to nor	-nreferred	1		
v. Discus	ssion by Board and		hair Decerbo moved to approve th			iges as	presented by
	by Board for		lagellan and Vice-Chair Ward seco			-	p. cocco,
	val of drugs for		5				
inclus	ion on the PDL.	А	vote was taken, and the results we	ere as follo	ws fro	m mer	nbers in
		at	ttendance (in favor, against, and al	ostentions	where	e applio	able):
					Yes	No	Abst.
		٠	Mark Decerbo, Pharm.D., Chair		\boxtimes		
		٠	Kate Ward, Pharm.D., Vice Chair		\boxtimes		
		٠	Joseph Adashek, MD		\boxtimes		
		•	Mark Crumby, Pharm.D.				\boxtimes
		•	Elizabeth Gonzalez, Pharm.D.		\boxtimes		
		•	Sapandeep Khurana, MD		\boxtimes		
		٠	Isabella Niezborala, Pharm.D.		\boxtimes		

	• Leana Ramirez, Pharm.D.		
	 Aditi Singh, MD 		
D. For Possible Action: Discussion			
and possible adoption of			
Sympathomimetics- Self-			
Injectable Epinephrine			
i. Public Comment	Telephonic and web comment was called	for and the phone lines were	
1. <u>Public Comment</u>	opened.	for, and the phone lines were	
	openedi		
	No public comment was provided.		
ii. Drug class review	Dr. Mishra recommended the Board cons	ider the class clinically and	
presentation by	therapeutically equivalent.		
MagellanRx			
iii. Discussion by Board and	Chair Decerbo moved to accept the class	as clinically and theraneutically	
action by Board to	equivalent presented by Magellan and Vi		
approve	motion.		
clinical/therapeutic			
equivalency of agents in	A vote was taken, and the results were as		
class.	attendance (in favor, against, and absten	tions where applicable):	
		Yes No Abst.	
	• Mark Decerbo, Pharm.D., Chair		
	Kate Ward, Pharm.D., Vice Chair		
	 Joseph Adashek, MD 		
	Mark Crumby, Pharm.D.		
	• Elizabeth Gonzalez, Pharm.D.	\boxtimes \Box \Box	
	Sapandeep Khurana, MD	\boxtimes \Box \Box	
	Isabella Niezborala, Pharm.D.		
	• Leana Ramirez, Pharm.D.		

	Aditi Singh, MD	
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended adding EpiPen and EpiPen Jr. on the PDL as preferred.	
 v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL. 	Board member Adashek moved to approve the proposed changes as presented by Magellan and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	
	Yes No Abst. Mark Decerbo, Pharm.D., Chair Image: Comparison of the system	
 For Possible Action: Discussion and possible adoption of Androgens. 		
i. <u>Public Comment</u>	 Telephonic and web comment was called for, and the phone lines were opened. Public comment was provided by John Phoenix, Nurse Practitioner with the Huntridge Family Clinic in Las Vegas. David Olsen from DHCFP. For a matter of clarification, the Board is reviewing drugs that are preferred and not preferred. This is not a 	

		formulary, it's a preferred drug list. All t today are covered on the formulary.	the drugs tha	it are p	resented		
11.	Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board consider the class clinically and therapeutically equivalent.					
iii.	Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Gonzalez moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Adashek seconded the motion.A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):					
		 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes ⊠ ⊠ □ ∞ ∞	No	Abst.		
iv.	Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended moving testosterone gel pump as preferred.					
V.	Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Gonzalez moved to approve the proposed changes as presented by Magellan and Chair Decerbo seconded the motion. A vote was taken, and the results were as follows from members in					

	attendance (in favor, against, and abstentions where applicable):				
	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes ⊠ □ □ □ □	No	Abst.	
F. For Possible Action: Discussion and possible adoption of Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists.					
i. <u>Public Comment</u>	Telephonic and web comment was called for opened. Public comment was provided by Mandeep Medical Affairs. Public comment was provided by Erin Nowa Science Liaison for AbbVie. Public comment was provided by Doctor Me Specialist.	iilval, P k, Medi	harmao cal Out	cist with Teva	
ii. Drug class review presentation by MagellanRx	Dr. Mishra recommended the Board conside therapeutically equivalent.	r the cla	ass clin	ically and	

 iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class. 	 Board Member Adashek moved to accept the class as clinically and therapeutically equivalent presented by Magellan and Board Member Gonzalez seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): 				
	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 	Yes ⊠ □ □ □ □ □ □ □ □ □ □ □ □ □	No	Abst.	
iv. Presentation of recommendations for PDL inclusion by MagellanRx	Dr. Mishra recommended to moving Emgality 100mg to non-preferred and leaving Emgality 120mg as preferred. Moving Qulipta and Ubrelvy to non-preferred.				
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	 Board Member Adashek moved to approve the proposed changes as presented by Magellan for Emgality 100 mg to be moved as non-preferred and the Emgality 120 mg to remain as preferred and that Qulipta and Ubrelvy to remain as preferred and Board Member Sapandeep Khurana seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): Yes No Abst. 				

	 Mark Decerbo, Pharm.D., Chair Kate Ward, Pharm.D., Vice Chair Joseph Adashek, MD Mark Crumby, Pharm.D. Elizabeth Gonzalez, Pharm.D. Sapandeep Khurana, MD Isabella Niezborala, Pharm.D. Leana Ramirez, Pharm.D. Aditi Singh, MD 		
G. MagellanRx Reports	 MRx Pipeline Immunology Behavioral Health Hematology Infectious Disease Biosimilar Overview Endocrine 		
H. Closing Discussion			
 Public comments on any subject 	No public comments were provided.		
ii. Date and location of the	Date: September 28, 2023.		
next meeting.	Location: Courtyard by Marriott Las Vegas Convention Center		
	3275 Paradise Road, Las Vegas, NV, 89109		
iii. Adjournment	Chairman Decerbo adjourned the meeting at 2:58 PN	1.	

Attachment A – Members of the Public in Attendance

Amy Hale, Janssen (Guest)	Jason C Bott	Levin, Amy, MD
Andre	JATD (Jonathan Delgado)	Lim, Luke
Booth, Robert	Joe Gelinas	Michael Pazirandeh
Cadenhead, Alisa	Joe Germain Jr.	Michael Zarob
Chris Syverson	John Deason	Nowak, Erin M
Colabianchi, Jeana	John Phoenix	Pulver, Lisa [JANUS]
Curtis, Larry L	Jonathan Cassaro	Roa, Ryan A
Fleuridas, AJ J	Jonkey, Ashley	Robert Greely
Gross, David	Joseph So	Sommers, Melissa
Hailey, Jennifer	Kelvin Yamashita	Stuart Pappas
Heidi Memmott	Lea Case	
Zimmer, Eileen	Susan Hertzberg (Guest)	

Attachment B – Submitted Written Comment

None